Cohance Lifesciences Divests CR Bio Unit to Chromo Labs for Rs 16 Crore Jun 20, 2025
Suven Pharma Set to Rebrand as Cohance Lifesciences Following Government Approval May 07, 2025
More news about Cohance Lifesciences
25Apr 25
Suven Pharma Secures Final Approval for Merger with Cohance Lifesciences
Suven Pharmaceuticals Limited has received final approval for its merger with Cohance Lifesciences, effective from May 1, 2025. The merged entity will operate as Cohance Lifesciences. Shareholders of Cohance Lifesciences will receive 11 equity shares of Suven Pharma for every 295 shares held, with May 8, 2025 set as the record date. The merger has obtained all necessary regulatory clearances, including NCLT approval and foreign investment clearance.
23Apr 25
Suven Pharma Secures Government Approval for Increased Foreign Investment Post-Merger
Suven Pharmaceuticals Limited has obtained approval from the Department of Pharmaceuticals, allowing for potential foreign investment above 74% following its merger with Cohance Lifesciences Limited. This approval, granted on April 22, 2025, is a crucial step in the merger process, which was initially approved by the Board on February 29, 2024. The National Company Law Tribunal sanctioned the Scheme of Amalgamation on March 27, 2025, following shareholder approval on November 28, 2024. The merger's Effective Date will be announced once all conditions are met.
28Mar 25
NCLT Approves Merger of Cohance Lifesciences with Suven Pharma
The National Company Law Tribunal (NCLT) has approved the merger between Cohance Lifesciences Limited and Suven Pharmaceuticals Limited. The merger will be effective from the first day of the month following the fulfillment of all conditions. Shareholders of Cohance will receive 11 shares of Suven for every 295 shares held. The combined entity aims to become a leading diversified CDMO in India, with expanded capabilities, an enhanced customer base, and access to multiple FDA-audited GMP facilities. The merger is expected to bring synergy benefits, accelerating growth and improving margins.